RxDoctor Payments Data

Georgeanna Welch

Family · Lubbock, TXNPI 1760600589

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by GSK at 29.0% of the total. Reporting peaked in 2021 at $672 and has fallen 88.1% since, to $80 in 2023.

$1,220in general payments, 2019–2025

Across 73 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$354
  • AbbVie$216
  • Regeneron Healthcare Solutions, Inc.$103
  • AstraZeneca$81
  • Boehringer Ingelheim$71
  • Takeda Pharmaceuticals U.S.A., Inc.$52
  • plus $344 from 13 others

What the payments were for

  • Food & beverage$1,14093%
  • Education$807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,220 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Other family in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →